# Kura Oncology

Source: https://onco.cc/companies/kura-oncology/  
OnCo record `kura-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Kura Oncology developed ziftomenib, the second menin inhibitor approved for leukaemia (November 2025), in partnership with Kyowa Kirin.

## Summary

Kura Oncology, based in San Diego and listed as KURA, developed ziftomenib, the second menin inhibitor approved for leukaemia, in partnership with Kyowa Kirin. Ziftomenib, sold as Komzifti, was approved on 13 November 2025 for relapsed or refractory NPM1-mutated acute myeloid leukaemia on the KOMET-001 trial, the KOMET-007 trials test it with 7+3 chemotherapy and with venetoclax and azacitidine in frontline disease, and the company also has a farnesyl-transferase inhibitor programme; the global Kyowa Kirin partnership dates from 2024. OnCo links it to acute myeloid leukaemia and to the AUGMENT-101 paper on revumenib, the first menin inhibitor. Whether menin inhibitors move into first-line combinations is the question KOMET-007 will answer. The FDA approval notice is linked.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: San Diego, CA
- Type: biotech
- Website: https://www.kuraoncology.com
- Ticker: KURA

## Sources

- FDA approval of Komzifti (Kura, 13 Nov 2025): https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-and-kyowa-kirin-announce-fda-approval-komziftitm

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/)
- drugs: [Ziftomenib](https://onco.cc/drugs/ziftomenib/)
- trials: [KOMET-001](https://onco.cc/trials/komet-001/), [Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML](https://onco.cc/trials/nct07007312/)
- key papers: [AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation](https://onco.cc/key-papers/paper-augment-101-revumenib-menin-nature-2023/)

---
JSON: https://onco.cc/api/v1/entities/kura-oncology.json